Ziltivekimab is an investigational anti-inflammatory biologic targeting the IL-6 pathway and is being studied in large cardiovascular and heart-failure outcome programs. Ongoing phase 3 studies evaluate event reduction in patients with cardiovascular disease/chronic kidney disease/inflammation and in heart failure with inflammation. It is not approved in any country.
Three comprehensive reports examine the monoclonal antibody landscape, covering CD47-targeted immunotherapy pipelines, competitive analysis of 180+ companies developing mAb therapeutics, and recombinant antibody market forecasts through 2033.
A review in The Lancet highlights emerging long-acting injectable therapies for hypertension that could reduce treatment to two doses annually instead of daily pills, with several candidates now in late-stage clinical trials.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07301034 |
A Research Study to Look at the Effect of Ziltivekimab on Plaque in the Blood Vessels of the Heart, Compared to Placebo, in People With a Heart Attack |
RECRUITING | PHASE3 |
| NCT07276282 |
Effects of Ziltivekimab on Coronary Atherosclerotic Burden in Patients With Acute Myocardial Infarction |
RECRUITING | PHASE3 |
| NCT06263244 |
Specifying the Anti-inflammatory Effects of Ziltivekimab |
RECRUITING | PHASE3 |
| NCT06200207 |
A Research Study Looking Into How Ziltivekimab Works Compared to Placebo in Participants With Heart Failure and Inflammation |
RECRUITING | PHASE3 |
| NCT06118281 |
ARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart Attack |
RECRUITING | PHASE3 |
| NCT05636176 |
A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and Inflammation |
RECRUITING | PHASE3 |
| NCT05379829 |
A Research Study of How the Medicine Ziltivekimab Works in the Body of Chinese Men and Women With Kidney Disease and Inflammation |
COMPLETED | PHASE1 |
| NCT04626505 |
Trial to Evaluate Reduction in Inflammation in Patients With Advanced Chronic Renal Disease Utilizing Antibody Mediated IL-6 Inhibition in Japan. |
COMPLETED | PHASE2 |
| NCT03926117 |
Trial to Evaluate Reduction in Inflammation in Patients With Advanced Chronic Renal Disease Utilizing Antibody Mediated IL-6 Inhibition |
COMPLETED | PHASE2 |
